Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of April 2026, with the report issued on April 27, 2026. The filing provides a specific update regarding litigation involving GSK's subsidiary, TESARO, Inc., and AnaptysBio, Inc., concerning a license agreement for the drug dostarlimab (brand name Jemperli).
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on legal proceedings and product status rather than financial performance data.
Material Changes and Litigation Update
- Court Ruling: The Delaware Chancery Court granted AnaptysBio's motion to dismiss TESARO's claim for anticipatory breach.
- Scope of Ruling: The ruling does not address the merits of the principal contractual dispute and has no impact on TESARO's remaining claim for declaratory judgment.
- Company Stance: GSK and TESARO maintain that AnaptysBio's allegations are without merit and intend to pursue the declaratory judgment claim at trial.
- Background: Litigation was initiated after AnaptysBio alleged TESARO failed to fulfill license requirements and threatened to revoke the license for dostarlimab.
Outlook, Management Commentary, and Risks
Product Outlook: Jemperli is approved in over 35 countries for certain endometrial cancers. GSK reports significant growth driven by label expansions in the US and EU. A clinical trial program is ongoing to evaluate dostarlimab for rectal, colon, and head and neck cancers.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in GSK's 2025 Annual Report on Form 20-F. The primary contingency highlighted is the ongoing litigation regarding the license agreement.
Key Facts for Investor Verification
- Verify the status of the remaining declaratory judgment claim against AnaptysBio following the dismissal of the anticipatory breach claim.
- Confirm the timeline and progress of the clinical trials for dostarlimab in rectal, colon, and head and neck cancers.
- Review the "Risk Factors" section of GSK's 2025 Annual Report on Form 20-F for detailed disclosures on litigation risks.
- Monitor future filings for any financial impact assessments related to the potential revocation of the dostarlimab license.